types of marijuana

Types of Marijuana and How THC Actually Makes You High at the Cellular Level

For employers building a workplace drug screening program, the question of what kind of marijuana a worker may have used matters less than most people assume — and the science behind why is genuinely useful. The popular categories — sativa, indica, and hybrid — are widely used on dispensary menus and in cannabis marketing, but modern peer-reviewed research has shown these labels are poor predictors of how a worker will actually be affected. The chemistry behind the high is the same regardless of strain label: THC crosses the blood-brain barrier, binds to a specific receptor protein on nerve cells, and disrupts how those cells communicate. The differences in subjective effect between cannabis products come from chemistry, not category.

This article covers the types of cannabis, what current science says about whether the categories predict effects, and the cellular-level mechanism by which THC produces a high. A companion article in this series covers the underlying biology of marijuana and the endocannabinoid system; another covers detection windows and workplace impairment.

The traditional categories: sativa, indica, ruderalis, hybrid

Botanically, the cannabis plant has historically been classified into three subspecies based on plant morphology — the physical characteristics of how the plant grows:

  • Cannabis sativa — Tall, narrow-leaved plants from equatorial regions (originally Thailand, Africa, South America). Long flowering periods, sometimes up to 14 weeks. Grows up to 5 meters in height.
  • Cannabis indica — Short, bushier plants with broader leaves, originally from mountainous regions of India, Pakistan, and Afghanistan. Shorter flowering periods.
  • Cannabis ruderalis — A smaller, hardy variety from Russia and Central Asia. Has very low THC concentrations on its own. Used primarily for breeding because of its autoflowering trait — it flowers based on age rather than light cycle.
  • Hybrid — Any cross between two or more of the above. Commercial breeding since the 1960s has produced thousands of hybrid cultivars; today, the vast majority of cannabis sold in U.S. dispensaries is genetically a hybrid.

The popular framework that sativa equals "energizing, cerebral, daytime" and indica equals "relaxing, body-focused, nighttime" has been around for decades. It dominates dispensary menus, cannabis marketing, and consumer expectations. But it is largely inherited from 18th-century botany applied to plant appearance — not from modern research on what cannabis chemistry actually does in the human body.

What the science actually says

Modern peer-reviewed cannabis research has substantially undermined the indica-versus-sativa framework as a predictor of effects. Multiple large-sample chemical analyses have come to the same conclusion.

The chemical analyses

A 2015 study published in Nature Plants found no consistent chemical or genetic distinction between products labeled "sativa" or "indica."

A 2022 study from Dalhousie University analyzing over 800 cannabis samples concluded that indica and sativa labels were not meaningful predictors of chemical composition. Two products both labeled "indica" could have dramatically different cannabinoid and terpene profiles, while products labeled differently could be chemically near-identical.

A more recent comprehensive study analyzing over 90,000 cannabis samples found that indica, sativa, and hybrid labels do not consistently align with the plant's actual chemical composition.

In a 2024 analysis of 140 commercial cultivars across categories, researchers compared terpene profiles across products labeled indica, sativa, and hybrid and found no meaningful differences between the groups. Products carrying different traditional labels were just as likely to share similar terpene profiles as they were to differ.

The conclusion across this body of research is consistent: the strain label on the package does not reliably predict the chemistry inside it, and therefore does not reliably predict the effect.

What does predict effects: the chemovar concept

What current research points to instead is the chemovar — short for "chemical variety." A chemovar describes a cannabis product by its actual measurable chemistry rather than by its species label. Two factors define a chemovar:

  1. Cannabinoid ratio — particularly the ratio of THC to CBD, plus presence of minor cannabinoids (CBG, CBN, CBC)
  2. Terpene profile — the aromatic compounds in cannabis that recent research suggests modulate cannabinoid effects

According to peer-reviewed research published in Scientific Reports (Nature) in 2021, terpenes are not just aromatic compounds — they actively modulate cannabinoid receptor activity. Different terpene profiles produce measurably different functional effects in the body. Specifically:

  • Myrcene-dominant profiles are associated with sedative, "couch-lock" effects regardless of whether the strain is labeled indica or sativa
  • Limonene-dominant profiles are associated with uplifting, mood-elevating effects
  • Pinene-dominant profiles are associated with focus and alertness
  • Linalool and caryophyllene contribute to relaxation and stress reduction

This is sometimes called the entourage effect — the idea that cannabinoids and terpenes work together synergistically, and the combined chemical profile drives the experience more than any single compound or category label.

What this means for an employer

For a workplace drug testing program, the most important takeaway is that knowing what category of cannabis a worker may have used is not useful information. There is no reliable way to predict from a strain label whether an employee will be more or less impaired, more or less drowsy, more or less affected on the job. The variable that matters is THC concentration and dose — and that varies enormously across products regardless of label.

The other practical takeaway: today's cannabis is significantly more potent than older research literature describes. Modern flower commonly contains 15% to 25% THC, and concentrates and edibles can deliver much higher doses in single servings. The acute effects from typical 2026 doses are stronger than the effects studied in older research, which makes "I only had a little" a less defensible position than it used to be.

How THC actually makes you high: the cellular mechanism

The actual biology of how THC produces a high is well-established and has nothing to do with strain category. Here is what happens at the cellular level when someone consumes cannabis.

Step 1: Absorption

When cannabis is inhaled, THC enters the bloodstream through the lungs within seconds. According to peer-reviewed pharmacokinetic research, peak blood levels occur within 6 to 10 minutes of inhalation. The bioavailability of inhaled THC is roughly 10% to 35% — meaning that fraction of the THC actually reaches systemic circulation.

When cannabis is ingested orally (edibles, oils, tinctures), THC takes a different and slower route. It is absorbed through the digestive system and passes through the liver before reaching the bloodstream — a process called first-pass metabolism. This converts a substantial portion of delta-9 THC into 11-hydroxy-THC, a metabolite that is itself psychoactive and, according to clinical research, often produces stronger and longer-lasting effects than inhaled THC. Oral onset is 30 minutes to 2 hours; peak effects can occur 2 to 4 hours after ingestion.

Step 2: Crossing the blood-brain barrier

This is the critical step that most non-scientific explanations skip. THC cannot produce a high without reaching the brain, and reaching the brain requires crossing the blood-brain barrier (BBB) — a highly selective protective layer of cells that separates the brain from the rest of the body's circulation.

According to peer-reviewed research published in PMC, THC crosses the blood-brain barrier rapidly because of one specific chemical property: lipophilicity. THC is fat-soluble (lipophilic) rather than water-soluble. The blood-brain barrier is a lipid (fat-based) membrane, so fat-soluble molecules pass through it readily, while water-soluble molecules largely cannot. This is why THC produces psychoactive effects within minutes of inhalation — the same property that makes THC linger in fatty tissue (the long detection-window problem) is what lets it reach the brain quickly in the first place.

Recent research has also documented that THC does not just pass through the blood-brain barrier; it interacts with cannabinoid receptors on the endothelial cells that form the barrier itself. A 2025 study published in Neuroscience found that THC exposure can cause measurable changes to blood-brain barrier integrity through CB1 receptor activation and oxidative stress mechanisms.

Step 3: Binding to the CB1 receptor

Once inside the brain, THC encounters the receptors it was designed (in evolutionary terms — by the cannabis plant's chemistry) to fit into. According to NIH-cited neuroscience research, the CB1 receptor is a G protein-coupled receptor (GPCR) embedded in the membranes of nerve cells, particularly concentrated on presynaptic neurons in regions of the brain involved in cognition, memory, motor control, and reward processing.

THC's molecular structure is similar enough to the body's own endocannabinoids (anandamide and 2-AG) that THC binds to and activates CB1 receptors. According to peer-reviewed research, THC is a partial agonist at CB1 — meaning it activates the receptor, but not as fully as the body's own natural cannabinoids do.

Step 4: What happens inside the nerve cell

This is where the high actually originates. When THC binds to a CB1 receptor on a nerve cell membrane, the receptor undergoes a conformational change that triggers a cascade of changes inside the cell:

  1. The receptor activates an intracellular G-protein (specifically the inhibitory Gi/o type)
  2. The G-protein suppresses adenylyl cyclase, an enzyme that produces cyclic AMP (cAMP) — a key cellular messenger
  3. Voltage-gated calcium channels close — preventing calcium from entering the cell
  4. Potassium channels open — letting potassium flow out of the cell
  5. The combined effect hyperpolarizes the presynaptic terminal — making the nerve cell less likely to fire and release neurotransmitters

The net result: THC binding to CB1 receptors makes affected nerve cells less likely to release the neurotransmitters they normally use to communicate with other nerve cells. This sounds simple but is profoundly disruptive in practice, because the brain regions where CB1 receptors are most concentrated are the regions that govern memory formation, attention, motor coordination, judgment, time perception, and reward processing.

Step 5: Why the high feels the way it does

The subjective experience of being high — the altered perception, the changes in mood, the impaired memory and coordination, the time distortion, the euphoria — is the downstream consequence of nerve cells failing to communicate normally in specific brain regions:

  • Disrupted communication in the hippocampus → impaired short-term memory formation
  • Disrupted communication in the orbitofrontal cortex → impaired attention, decision-making, and ability to shift focus
  • Disrupted communication in the cerebellum and basal ganglia → impaired balance, coordination, and reaction time
  • Activation of dopamine release in the reward system → euphoria, the sense of pleasure that contributes to marijuana's addictive properties

The reason the effects feel like they happen "all at once" is that THC reaches CB1 receptors throughout the brain at roughly the same time, and the disruption to nerve cell communication is happening simultaneously in all these regions. This is also why even a moderate dose impairs multiple distinct cognitive and motor functions at the same time — it's not affecting one system; it's reducing communication efficiency across an entire signaling network.

What this means for workplace screening

For employers, the cellular-level science explains a few practical things that often get asked:

  • Why a worker can be impaired without "looking" obviously high. The disruption happens at the cellular level in specific brain regions. Some workers compensate visibly better than others, but the underlying impairment to memory, reaction time, and judgment is happening regardless.
  • Why effects can feel "different" between products despite identical THC content. The terpene profile and minor cannabinoids in a given product modulate how the THC interacts with the system. This is real — it is not predicted by the strain label.
  • Why edibles produce stronger and longer-lasting impairment. First-pass metabolism converts more of the THC into 11-hydroxy-THC, which is itself psychoactive and has a longer duration in the body.
  • Why workers can be impaired the morning after evening use, particularly with edibles or high doses. The impairment window can extend 6 to 8 hours or more, and chronic users who have built up THC stores in fatty tissue can have residual effects beyond the typical acute window.
  • Why "I only used a low-THC product" is not a reliable defense against impairment claims. The same THC molecule binds to the same CB1 receptors regardless of the label on the package. Dose matters; label does not.

Final takeaway

Cannabis is sold under three traditional category labels — sativa, indica, and hybrid — that have been around since 18th-century botany. Modern peer-reviewed research has shown these labels are poor predictors of how cannabis will affect a person; what predicts effect is the chemovar, defined by cannabinoid ratio and terpene profile. The cellular mechanism that produces a high is the same regardless of category: THC's fat-soluble structure lets it cross the blood-brain barrier rapidly, where it binds to CB1 receptors on nerve cells, suppresses neurotransmitter release through a G-protein cascade, and disrupts normal communication in brain regions controlling memory, attention, motor coordination, and judgment. For employer drug screening programs, the practical takeaway is that the strain label on a product does not predict whether or how a worker will be impaired — what matters is THC concentration, dose, and how recently it was consumed.

Sourcing rapid tests for your workplace screening program?

At My BIO TESTS®, we supply rapid, CLIA-Waived FDA 510(k)–cleared drug screening tests, plus Employer & Insurance Use Only and Forensic Use Only options for employer programs. We focus on helping safety-sensitive and multi-location organizations standardize fast, reliable onsite screening workflows with trusted product supply.

Building or updating your workplace drug testing program?

→ See rapid urine and oral fluid drug screens for employers

Or call 737-333-5566 | email info@mybiotests.com

Sources

  • National Institute on Drug Abuse, "Cannabis (Marijuana) — How does marijuana produce its effects?" (current edition)
  • National Institutes of Health / PMC, "Cannabinoids, Blood–Brain Barrier, and Brain Disposition"
  • National Institutes of Health / PMC, "Mechanisms of Action and Pharmacokinetics of Cannabis"
  • National Institutes of Health / PMC, "Molecular Mechanism and Cannabinoid Pharmacology"
  • Nature Plants, genetic and chemical analysis of cannabis cultivars (2015)
  • Scientific Reports (Nature), "Cannabis sativa terpenes are cannabimimetic and selectively enhance cannabinoid activity" (2021)
  • Dalhousie University, chemical profile analysis of 800+ cannabis samples (2022)
  • Neuroscience (ScienceDirect), "Δ9-tetrahydrocannabinol induces blood-brain barrier disruption: Involving the activation of CB1R and oxidative stress" (2025)
  • American Medical Association, "All about cannabis pharmacology" (2024)

Disclosure: My BIO TESTS® sells rapid urine and oral fluid drug screening tests in three regulatory categories: CLIA-Waived FDA 510(k)–cleared, Employer & Insurance Use Only, and Forensic Use Only. Selection of the appropriate category depends on your testing program and use case. Positive results from any rapid screening test are presumptive and should be confirmed by an HHS-certified laboratory and reviewed by a qualified Medical Review Officer (MRO). This content is educational and is not medical, legal, or scientific advice for any specific testing program. Consult qualified professional counsel before making policy or testing decisions for your workforce.

Last updated: May 2026

Back to blog